KRAS gene mutations are found in about 85% of cases, and they are critical for initiating and maintaining pancreatic tumors by encoding a Guanosine Triphosphatase (GTPase) enzyme that regulates essential intracellular signaling pathways, including rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) [20,21]. Here, AKT1 is linked to pancreatic neoplasm.